Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589893 | 0.92 | ME2 (0.36) | ESR1ESR2 | |
| SCHEMBL590107 | 0.79 | HRH1 (0.37) | — | |
| SCHEMBL591223 | 0.78 | TLR8 (0.32) | — | |
| SCHEMBL3880704 | 0.78 | HTR3A (0.35) | GAA | |
| SCHEMBL4072273 | 0.78 | CETP (0.37) | MAPTGAA | |
| SCHEMBL12921206 | 0.75 | CRHR1 (0.32) | — | |
| SCHEMBL3046737 | 0.74 | HTR3A (0.36) | ESR1ESR2MAPTGAA | |
| SCHEMBL3046733 | 0.74 | HTR3A (0.36) | ESR1ESR2MAPTGAA | |
| SCHEMBL588851 | 0.74 | CDK1 (0.34) | — | |
| SCHEMBL7715595 | 0.73 | CCNA2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | ESR1 2178/4885ESR2 1737/4885SLC27A1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.